Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Beginning Cash Balance: 2009-2025

Historic Beginning Cash Balance for Aytu Biopharma (AYTU) over the last 17 years, with Jun 2025 value amounting to $20.0 million.

  • Aytu Biopharma's Beginning Cash Balance rose 54.71% to $31.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.1 million, marking a year-over-year increase of 0.72%. This contributed to the annual value of $20.0 million for FY2025, which is 12.96% down from last year.
  • Aytu Biopharma's Beginning Cash Balance amounted to $20.0 million in FY2025, which was down 12.96% from $23.0 million recorded in FY2024.
  • Aytu Biopharma's Beginning Cash Balance's 5-year high stood at $49.9 million during FY2022, with a 5-year trough of $19.4 million in FY2023.
  • Moreover, its 3-year median value for Beginning Cash Balance was $20.0 million (2025), whereas its average is $20.8 million.
  • As far as peak fluctuations go, Aytu Biopharma's Beginning Cash Balance surged by 337.68% in 2021, and later plummeted by 61.20% in 2023.
  • Aytu Biopharma's Beginning Cash Balance (Yearly) stood at $48.3 million in 2021, then increased by 3.24% to $49.9 million in 2022, then tumbled by 61.20% to $19.4 million in 2023, then climbed by 18.72% to $23.0 million in 2024, then dropped by 12.96% to $20.0 million in 2025.